Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Multidrug-resistant Pseudomonas antibiotic with robust in vivo efficacy and novel target (undisclosed) More
A novel mutagenesis system that enables the creation of unmarked and targeted deletions in Burkholderia strains. More
Scientists at the University of Edinburgh have identified a novel therapeutic strategy for the treatment of inflammatory disorders. More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
A powerful technology for the simultaneous monitoring of protein kinase activities in cell and tissue extracts using a multiplexed electrochemical assay More
This cell line may be used for elucidation of the mechanisms of CF, testing candidate complementary genes for correction of the observed CF abnormalities, and for developing and testing therapeutic CF drugs. More
POL6014 is a very potent, reversible, competitive antagonist of human neutrophil elastase More
Mismatch-targeted transposition of Mu: a new strategy to map genetic polymorphism. More
Your selection
Browse By
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us